千金药业(600479) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥952,803,503.92, representing a year-on-year increase of 4.44%[5] - The net profit attributable to shareholders for the same period was ¥39,977,477.56, reflecting a growth of 5.43% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses decreased by 3.38% to ¥35,691,975.65[5] - Basic earnings per share for Q1 2022 stood at ¥0.0930, an increase of 2.65%[6] - Total operating revenue for Q1 2022 was approximately ¥952.80 million, an increase of 4.9% compared to ¥912.28 million in Q1 2021[19] - Net profit for Q1 2022 reached approximately ¥51.05 million, representing a 11.4% increase from ¥45.74 million in Q1 2021[20] - The total profit for Q1 2022 was approximately ¥59.44 million, an increase of 10.4% from ¥53.59 million in Q1 2021[20] Cash Flow - The net cash flow from operating activities was negative at -¥89,031,314.87, a decline of 261.84% year-on-year[5] - The net cash flow from operating activities for Q1 2022 was negative at approximately -¥89.03 million, compared to a positive ¥55.01 million in Q1 2021[22] - Cash inflow from operating activities totaled 195,107,331.20 in Q1 2022, down 40.2% from 326,585,910.75 in Q1 2021[30] - Cash outflow from operating activities was 279,947,348.03 in Q1 2022, a decrease of 31.6% compared to 409,315,100.61 in Q1 2021[30] - The net cash flow from investing activities was 104,256,819.90 in Q1 2022, down 25.7% from 140,297,685.05 in Q1 2021[31] - Cash inflow from investing activities increased significantly to 445,802,549.80 in Q1 2022, compared to 198,771,224.76 in Q1 2021, marking a growth of 124.8%[31] - The net cash flow from financing activities was 48,590,000.00 in Q1 2022, compared to 0.00 in Q1 2021, indicating a new source of cash inflow[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,182,747,417.59, up 3.02% from the end of the previous year[6] - The total liabilities as of March 31, 2022, were CNY 1,431,758,107.61, compared to CNY 1,360,309,325.05 at the end of 2021, marking an increase of about 5.2%[16] - The total equity attributable to shareholders increased to CNY 2,190,368,512.89 from CNY 2,150,385,209.84, reflecting a growth of approximately 1.9%[16] - The company's total current assets reached CNY 1,968,347,688.81 as of March 31, 2022, compared to CNY 1,882,965,787.77 at the end of 2021, marking an increase of about 4.54%[25] - The total liabilities as of March 31, 2022, were CNY 951,766,307.46, up from CNY 890,795,057.83 at the end of 2021, which is an increase of approximately 6.84%[26] Receivables and Inventory - Accounts receivable increased by 69.47% primarily due to changes in the company's credit policy[9] - Other receivables surged by 337.37% mainly due to increased advances and guarantees[9] - Accounts receivable rose significantly to CNY 379,156,692.29 from CNY 223,724,517.58, representing an increase of approximately 69.5%[14] - The company's inventory decreased to CNY 515,093,770.82 from CNY 547,778,902.92, showing a decline of about 6.0%[14] - The company reported a decrease in accounts receivable from CNY 156,148,871.64 in Q1 2021 to CNY 125,179,397.20 in Q1 2022, a decline of about 19.87%[25] Research and Development - The company incurred research and development expenses of approximately ¥25.17 million in Q1 2022, slightly down from ¥26.93 million in Q1 2021[19] - Research and development expenses for the first quarter of 2022 were CNY 11,862,895.56, slightly higher than CNY 11,115,757.65 in the first quarter of 2021, showing an increase of about 6.71%[27] Financial Position - The weighted average return on equity increased by 0.18 percentage points to 1.84%[6] - The company's retained earnings increased to CNY 970,711,015.00 from CNY 930,733,537.44, reflecting a growth of about 4.3%[16] - The company's short-term borrowings were CNY 66,358,031.52, a slight decrease from CNY 67,085,909.99, reflecting a reduction of about 1.1%[15] - The company's financial expenses showed a significant improvement, with a net financial income of CNY 1,388,845.30 in Q1 2022 compared to a loss of CNY 4,840,184.79 in Q1 2021[27] Accounting Standards - The company has not applied the new accounting standards starting from 2022, indicating a potential impact on future financial reporting[32]